Similar to the molecules described above, BeiGene’s MAP4K1 inhibitor increases T cell responses and causes tumor growth inhibition in syngeneic mouse models (GL261, CT26, and EMT6 breast cancer). Here, MAP4K1 is linked to neoplasm.